Cell Therapy Slashes COVID-19 Death Risk by 60%
Cell therapy has been shown to significantly reduce the mortality risk in COVID-19 patients based on an analysis of nearly 200 clinical trials conducted since 2020.
Cell therapy has been shown to significantly reduce the mortality risk in COVID-19 patients based on an analysis of nearly 200 clinical trials conducted since 2020.
A new study demonstrates how effective specific types of exercise training can be to enhance lung function for those with asthma.
Neonatal pulmonary disorders may require additional respiratory support beyond supplemental oxygen, such as nasal CPAP, HFNC, nasal BiPAP, NIPPV, nHFOV, or even NIV-NAVA.
An FDA advisory committee determined that phenylephrine, common in brands like Benadryl and Mucinex, is ineffective as a nasal decongestant.
A new SARS-CoV-2 vaccination designed to induce the production of Immunoglobulin A orally in monkeys produced the necessary antibodies against the disease without discernable side effects.
Mallinckrodt Manufacturing is recalling its one-way valve, 22F x 22M, due to devices not opening properly, which prevents or reduces the flow of ventilated air or oxygen.
Despite advancements, a Michigan Medicine study finds that the death rate for pulmonary embolism remains high and unchanged in recent years—more often killing men, Black patients, and those from rural areas.
Mount Sinai's newly developed ventilatory burden offers a potentially more effective alternative to the traditional AHI in assessing severity in sleep apnea patients.